Aquestive Therapeutics Stock (NASDAQ: AQST)

Aquestive Therapeutics (NASDAQ:AQST) Stock

Aquestive Therapeutics

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics Inc

WIIM

Evotec shares are trading higher. The company reported FY24 financial results.

Better Choice Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#NYSE">BTTR</a>) ("Better Choice" or the "Company"), a pet health and wellness company, today announced that its Board of Directors has reinstated its stock repurchase program and increased authorization up to $6.5 million of its outstanding shares of common stock, until December 31, 2025. The Company repurchased 102,405 common shares at an average price of $1.9869 per share under the previous $5 million stock repurchase program, which expired on December 31, 2024.
Michael Young, Chairman of Better Choice, commented, "After repurchasing 102,405 common shares under our previous repurchase program in 2024, it is in the best interest of our shareholders to reinstate this program and increase the authorized amount up to $6.5 million as we strongly believe our equity to be undervalued."

News

Buybacks

BTTR

Better Choice Company Has Reinstated Its Stock Repurchase Program And Increased Authorization Up To $6.5M Of Its Outstanding Shares Of Common Stock, Until December 31, 2025

LBRT

Liberty Energy shares are trading higher after the company reported better-than-expected Q1 revenue results.

Keefe, Bruyette &amp; Woods analyst Brady Gailey maintains First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) with a Market Perform and lowers the price target from $24 to $22.

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Market Perform on First Horizon, Lowers Price Target to $22

Small Cap Consumer Research analyst Eric Beder reiterates Betterware de Mexico SAPI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>) with a Buy and maintains $22.5 price target.

Reiteration

BWMX

Small Cap Consumer Research Reiterates Buy on Betterware de Mexico SAPI, Maintains $22.5 Price Target

<ul>
<li>Sol-Gel to receive $16 million during 2025</li>
<li>Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trial</li>
<li>SGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achieved</li>
<li>Sol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annually</li>
<li>SGT-210 Phase 1b trial in Darier patients is ongoing; 50% of the patients have already completed the trial</li>
</ul>
NESS ZIONA, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLGL#NASDAQ">SLGL</a>), a clinical-stage dermatology company, today announced it has entered into a product purchase agreement with a subsidiary of Mayne Pharma Group Limited (ASX: MYX) (Mayne Pharma) for the sale and exclusive license of the U.S. rights to EPSOLAY and TWYNEO. Under the terms of the agreement, Sol-Gel will receive a total of $16 million in two installments: $10 million in the second quarter of 2025 and $6 million in the fourth quarter of 2025, which is expected to extend the Company's cash runway into the first quarter of 2027. This agreement was executed following the mutual termination by Sol-Gel and Galderma of the exclusive five-year license agreement in the U.S. for both products.

SLGL

Sol-Gel Announces Product Purchase Agreement With Mayne Pharma's Unit For Sale And Exclusive License Of U.S. Rights To EPSOLAY and TWYNEO; Sol-Gel to Receive $16M During 2025

Jefferies analyst Matthew Taylor maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Hold and raises the price target from $135 to $137.

Jefferies Maintains Hold on Abbott Laboratories, Raises Price Target to $137

GSBC

Great Southern Bancorp shares are trading lower. The company reported Q1 financial results.

VERB

Verb Technology Completed Acquisition Of Lyvecom For $5.2M In Cash, Stock, And Debt Repayment, With Potential $3M Earn-Out

Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintains FB Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBK#NYSE">FBK</a>) with a Market Perform and lowers the price target from $58 to $52.

Keefe, Bruyette & Woods Maintains Market Perform on FB Financial, Lowers Price Target to $52

American Express Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) reported fiscal first-quarter 2025 results on Thursday. The stock price declined <a href="https://www.benzinga.com/pressreleases/25/04/b44859812/american-express-delivers-strong-first-quarter-results-with-revenue-of-17-0-billion-up-7-or-8-on-a" target="_blank" rel="noreferrer noopener">after the report</a>.
The company reported revenue&nbsp;(net of interest expense) growth of 7% year-on-year to $16.97 billion, topping the&nbsp;analyst <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus estimate of&nbsp;$16.94 billion</a>.&nbsp;
The revenue increase was primarily driven by strong Card Member spending, higher net interest income supported by growth in revolving loan balances, and accelerated card fee growth.
GAAP EPS of $3.64 topped the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $3.47</a>.&nbsp;
Read Next: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/44811593/bank-of-america-ceo-says-consumer-continues-to-spend-and-maintain-healthy-credit-quality-sticks-to-annual-outlook" rel="noreferrer noopener">Despite Tariff Turmoil, Bank Of America CEO Says Consumer Is ‘Continuing To Spend' (UPDATED)</a>
Card Member spending or Billed Business grew 6% Y/Y to $387.4 billion. U.S. Consumer Services revenue&nbsp;was $8.25 billion,&nbsp;<a target="_blank" href="https://ir.americanexpress.com/events/default.aspx" rel="noreferrer noopener">up 7%&nbsp;Y/Y</a>. Commercial Services revenue was $4.04 billion, up 2%&nbsp;Y/Y.
International Card Services revenue was $2.94 billion, up 13% year over year, and Global Merchant and Network Services revenue was $1.82 billion, down 2.9% year over year.
Total expenses increased by 10%&nbsp;Y/Y&nbsp;to $12.5 billion, primarily reflecting higher variable customer engagement costs.&nbsp;
Provision for credit losses stood at $1.2 billion, compared with $1.3 billion a year ago, reflecting a modest net reserve build.&nbsp;
FY25 Outlook: Amex&nbsp;<a target="_blank" href="https://www.benzinga.com/25/01/43190630/american-express-q4-record-spending-and-card-acquisitions-9-topline-growth-17-dividend-hike" rel="noreferrer noopener">reiterated a revenue outlook of</a> $71.22 billion-$72.54 billion (up by 8%-10% Y/Y) versus&nbsp;a&nbsp;consensus of $71.34 billion subject to the macroeconomic environment. It reaffirmed EPS of $15.00–$15.50 versus&nbsp;the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">consensus of $15.25</a>.
"Based on the steady spend and credit trends we have seen to date and the current economic outlook, we are maintaining our full-year guidance for revenue growth of 8 to 10 percent and EPS of $15.00 to $15.50, in line with the ranges we provided in January, subject to the macroeconomic environment," Chairman and CEO Stephen J. Squeri said.
Last week, BofA Securities analyst&nbsp;Mihir Bhatia&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/upgrades/25/04/44768565/american-express-receives-upgrade-what-makes-this-stock-so-appealing" rel="noreferrer noopener">upgraded&nbsp;American Express</a> from Neutral to Buy and lowered the&nbsp;price target from&nbsp;$325&nbsp;to&nbsp;$274&nbsp;citing its high-quality customer base should drive more durable earnings while keeping credit losses in check. Bhatia noted the current downtick offers long-term oriented investors an opportunity to buy a high-quality company at a reasonable valuation.
The analyst predicts that higher-income consumers, who comprise American Express' customer base, will prove to be more resilient from a credit and spending perspective. Amex stock is down over 15% year-to-date.
Price Action:&nbsp;AXP stock is down 0.76% at $250.99 premarket&nbsp;at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44851295/asml-cfo-incorporates-tariff-impact-in-outlook-reveals-strong-demand-for-advanced-euv-and-high-na-systems" target="_blank" rel="noreferrer noopener">ASML CFO Incorporates Tariff Impact In Outlook, Reveals Strong Demand For Advanced EUV And High NA Systems</a></li>
</ul>
Photo via Shutterstock

Earnings

Guidance

American Express Q1 Card Spending Strong, CEO Maintains Annual Outlook Contingent On Economic Climate

CORRECTION: American Express Sees FY25 Adj. EPS $15.00-$15.50 Vs $15.23 Estimate

WEXFORD, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) ("the Company" or "COEPTIS"), a pioneering technology firm at the forefront of innovative biotechnology solutions, is excited to announce the establishment of a new co-working technology hub in India in partnership with U.S.-based NexGenAI Solutions Group (<a href="https://www.globenewswire.com/Tracker?data=KiBtkIXCLqA_RVURcwmLrx5Poq5K4SbeO3P3x7XRKPukrxcxDMDPrS-zzemfGMF4UxK9sxoRd4YXJJdVQ37wCS9qUtM1ztvEkhoBpmcJoZE=">https://nexgenai.io</a>) and Indian technology firm Ishvara Tech Consulting LLP.

COEP

COEPTIS Partners With NexGenAI Solutions Group And Ishvara Tech Consulting To Establish New Co-Working Technology Hub In India

ManpowerGroup shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results. Additionally, the company issued Q2 EPS guidance below estimates.

Benchmark analyst Robert Wasserman initiates coverage on XOMA Royalty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) with a Buy rating and announces Price Target of $35.

Initiation

XOMA

Benchmark Initiates Coverage On XOMA Royalty with Buy Rating, Announces Price Target of $35

Fidelity National Information Services Preliminary Q1 2025 Revenue Of $2,532M; Preliminary Q1 2025 Adjusted EPS Estimated At $1.21 Per Share

Keefe, Bruyette &amp; Woods analyst David Konrad maintains Citizens Financial Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>) with a Market Perform and lowers the price target from $49 to $45.

Keefe, Bruyette & Woods Maintains Market Perform on Citizens Financial Group, Lowers Price Target to $45

As of April 17, 2025, three stocks in the materials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">United States Antimony Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAMY#NYSE">UAMY</a>)</h3>
<ul>
<li>On April 11, United States Antimony secured a $5 million line of credit. &#8220;We&#8217;re pleased to establish this new credit facility with Truist Bank, which not only augments our working capital capabilities, but also demonstrates growing confidence in our business and long-term potential,&#8221; said Richard (Rick) Isaak, Senior Vice President and CFO of U.S. Antimony. The company's stock jumped around 103% over the past month and has a 52-week high of $3.60.</li>
<li>RSI Value: 83.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>UAMY Price Action: Shares of United States Antimony gained 7.1% to close at $3.49 on Wednesday.</li>
<li>Edge Stock Ratings: 99.82 Momentum score with Value at 10.46.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/UAMY"><img loading="lazy" decoding="async" width="477" height="172" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17054128/image-16.png" alt="" class="wp-image-876204" style="width:338px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17054128/image-16.png 477w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17054128/image-16-300x108.png 300w" sizes="(max-width: 477px) 100vw, 477px" /></a></figure>
<h3 class="wp-block-heading">Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)</h3>
<ul>
<li>On April 16, Newmont finalized the previously disclosed sales of its Akyem operation in Ghana and its Porcupine operation in Canada. &#8220;Today, I am pleased to announce the successful completion of our non-core asset divestiture program with the sale of Akyem and Porcupine, generating total after-tax cash proceeds of approximately $850 million before closing adjustments,&#8221; said Tom Palmer, Newmont&#8217;s President and Chief Executive Officer. The company's stock gained around 18% over the past month and <a href="https://www.benzinga.com/quote/NEM">has a 52-week high</a> of $58.72.</li>
<li>RSI Value: 75.8</li>
<li>NEM Price Action: Shares of Newmont gained 2.5% to close at $55.95 on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Royal Gold Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLD#NASDAQ">RGLD</a>)</h3>
<ul>
<li>On April 14, Scotiabank analyst Tanya Jakusconek upgraded Royal Gold from Sector Perform to Sector Outperform and raised the price target from $166 to $189. The company's stock gained around 20% over the past month and has a <a href="https://www.benzinga.com/quote/RGLD">52-week high</a> of $191.22.</li>
<li>RSI Value: 77.9</li>
<li>RGLD Price Action: Shares of Royal Gold gained 0.8% to close at $186.45 on Wednesday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>. 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44857276/netflix-unitedhealth-group-and-3-stocks-to-watch-heading-into-thursday">Netflix, UnitedHealth Group And 3 Stocks To Watch Heading Into Thursday</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

RGLD

UAMY

Top 3 Materials Stocks That Are Ticking Portfolio Bombs

QXO shares are trading lower after the company announced its intent for a $500 million public offering.

Outlook
Bockhorst continued, "Our first quarter results demonstrate the resilience and durability of our replacement-driven business amidst a volatile macroeconomic environment. As previously communicated, we will face difficult prior-year comparisons in the upcoming second quarter of 2025. Nevertheless, the attractive fundamentals of the water industry, and our ability to add value to customers with an innovative and reliable portfolio of solutions, support our average high-single-digit long-term revenue growth outlook.
We delivered record gross margins in the first quarter, benefiting from a notably favorable combination of product and customer sales mix. While this clearly demonstrates that the structural mix benefit of technology adoption within our business is real, given the evolving tariff picture and related uncertainty, we believe it is prudent to maintain our normalized gross margin range of 38-40% at this time. At present, we are confident in our ability to manage certain tariff-related cost challenges. Our history of strong operational execution, particularly in the management of our supply chain, manufacturing footprint, and value-based pricing strategy, underscores our proven ability to control what we can control in a turbulent economic environment.
The addition of SmartCover earlier this year emphasizes the growing extensibility and appeal of our BlueEdge suite of products and services. Our customers continue to feel the impact of extreme weather events, which makes SmartCover's stormwater management offering a compelling part of our portfolio. Although still early in the integration, we're on track for delivering anticipated sales and cost synergies. Importantly, our solid balance sheet gives us the financial flexibility to fund the capital allocation priorities supporting our long-term strategy, including value-added, disciplined acquisitions.
Bockhorst concluded, "We were proud to be named for the third consecutive year to Barron's 2025 list of 100 Most Sustainable Companies. We carry a responsibility for protecting the world's most precious resource. This gives our employees a sense of purpose, which powers our innovation engine, delivers solutions to our end markets, and generates steady long-term shareholder value."

Badger Meter Says "Our First Quarter Results Demonstrate The Resilience And Durability Of Our Replacement-driven Business Amidst A Volatile Macroeconomic Environment. We Will Face Difficult Prior-Year Comparisons In The Upcoming Second Quarter Of 2025"

Press Releases

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film

Health Care

General

Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five

Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives

Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference

Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

Aquestive Therapeutics to Participate in Two Upcoming Conferences in March

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film

Comments

Aquestive Therapeutics

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL